


PTO-1449 REPRODUCED

**INFORMATION DISCLOSURE CITATION  
IN AN APPLICATION**

August 2, 2005

(Use several sheets if necessary)



ATTORNEY DOCKET NO.

2732.1016-029

APPLICATION NO.

10/719,432

APPLICANT

Spiros Jamas *et al.*

FILING DATE

November 21, 2003

CONFIRMATION NO.

5697

GROUP

1614

**FOREIGN PATENT DOCUMENTS**

		DOCUMENT NUMBER Country Code-Number-Kind Code (if known)	DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	TRANSLATION	
					YES	NO
	AL2	WO 94/04163 A1	03-03-1994	PCT International		
	AL3	EP 0 416 343 A2	03-13-1991	EPC		

EXAMINER

DATE CONSIDERED

PTO-1449 REPRODUCED  <b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b>  <b>August 2, 2005</b>  (Use several sheets if necessary)	ATTORNEY DOCKET NO. 2732.1016-029		APPLICATION NO. 10/719,432	
	APPLICANT Spiros Jamas <i>et al.</i>			
	FILING DATE November 21, 2003		CONFIRMATION NO. 5697	GROUP 1614

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

AX	Sherwood, E.R., <i>et al.</i> , "Soluble Glucan and Lymphokine-Activated Killer (LAK) Cells in the Therapy of Experimental Hepatic Metastases," <i>Chemical Abstracts</i> , 108:179752v (1988).
AW2	Vestnick Federalniho Uradu Pro Vynalezky, 10:111 (1989).
AX2	Vestnick Federalniho Uradu Pro Vynalezky, 11:122-123 (1989).
AV3	Jamas, S. <i>et al.</i> , "A Novel Class of Macrophage-Activating Immunomodulators," ACS Symposium Series, <i>Polymeric Drugs and Delivery Systems</i> , Chapter 5, pp. 44-51 (1991).
AX4	Sasaki, T. <i>et al.</i> , "Antitumor Activity of Degraded Products of Lentinan: Its Correlation with Molecular Weight," <i>Gann</i> , 67:191-195 (1976).
AY4	Di Luzio, <i>et al.</i> , "Comparative Tumor-Inhibitory and Anti-Bacterial Activity of Soluble and Particulate Glucan," <i>Int. J. Cancer</i> , 24:773-779 (1979).
AZ4	Burgaleta, C. and Golde, D.W., "Effect of Glucan of Granulopoiesis and Macrophage Genesis in Mice," <i>Cancer Research</i> , 37:1739-1742 (1977).
AR5	Kenyon, A.J., "Delayed Wound Healing in Mice Associated with Viral Alteration of Macrophages," <i>Am. J. Vet. Res.</i> , 44(4):652-656 (1983).
AT5	Babineau, T., <i>et al.</i> , "Randomized Multicenter Phase I/II Trial of a Macrophage-Specific Immunomodulator (PGG-Glucan) in High Risk Surgery Patients," Surgical Infection Society Meeting, April, 29, 1994.
AX5	Norton, J.A., "Biological Therapy of Sepsis", <i>Annals of Surgery</i> , 220(5):599-600 (1994).
AY5	"Tumor Necrosis Factor: A Biological Enigma," Science Impact, pp. 5-6, June 1989.
AZ5	Dinareello, C.A. and Neta, R., "An Overview on Interleukin-1 as a Therapeutic Agent", <i>Biotherapy</i> , 1:245-254 (1989).
AR6	Van der Meer, J.W.M., <i>et al.</i> , "Concentrations of Immunoreactive Human Tumor Necrosis Factor Alpha Produced by Human Mononuclear Cells In Vitro," <i>Journal of Leukocyte Biology</i> , 43:216-223 (1988).
AS6	Dinareello, C.A., "Interleukin-1," <i>Reviews of Infectious Diseases</i> , 6(1):51-95 (1984).

EXAMINER	DATE CONSIDERED
----------	-----------------

PTO-1449 REPRODUCED  <b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b>  <b>August 2, 2005</b>  (Use several sheets if necessary)	ATTORNEY DOCKET NO. <b>2732.1016-029</b>		APPLICATION NO. <b>10/719,432</b>	
	APPLICANT <b>Spiros Jamas <i>et al.</i></b>			
	FILING DATE <b>November 21, 2003</b>	CONFIRMATION NO. <b>5697</b>	GROUP <b>1614</b>	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
	AT6	Duvic, M., <i>et al.</i> , "Glucan-Induced Keratoderma in Acquired Immunodeficiency Syndrome," <i>Arch Dermatol.</i> , 123:751-756
	AU6	Adachi, Y., <i>et al.</i> , "Macrophage Activation in Vitro by Chemically Cross-Linked (1-3)- $\beta$ -D-Glucans," <i>Chem. Pharm. Bull.</i> , 38(4):988-992 (1990).
	AV6	Sietsma, J.H. and Wessels, J.G.H., "Solubility of (1-3)- $\beta$ -D/(1-6)- $\beta$ -D-Glucan in Fungal Walls: Importance of Presumed Linkage between Glucan and Chitin", <i>J. Gen. Microbiology</i> , 125:209-212 (1981).

EXAMINER	DATE CONSIDERED
----------	-----------------